Crossmark

Dkk1 KO Mice Treated with Sclerostin Antibody Have Additional Increases in Bone Volume

Crossref DOI link: https://doi.org/10.1007/s00223-018-0420-6

Published Online: 2018-05-29

Published Print: 2018-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Morse, Alyson

Cheng, Tegan L.

Schindeler, Aaron

McDonald, Michelle M.

Mohanty, Sindhu T.

Kneissel, Michaela

Kramer, Ina

Little, David G.
License Information

Text and Data Mining valid from 2018-05-29
More Information

Article History

Received: 24 January 2018

Accepted: 5 April 2018

First Online: 29 May 2018

Compliance with Ethical Standards

:

: The authors received materials support (Scl-Ab) for this study from Novartis Pharma AG (Basel, Switzerland) and Mereo BioPharma (London, UK). Prof Little has received additional funding and materials support from Novartis Pharma AG and Mereo BioPharma for pre-clinical research separate to this submission and is a consultant for Orthopediatrics. Prof Little and A/Prof Schindeler have received funding support from Amgen Inc., UCB Pharma, N8 Medical, and Celgene for pre-clinical research separate to this submission. Dr McDonald received salary support from the IBMS Greg Mundy Fellowship and receives a Practitioner Fellowship (National Health & Medical Research Council). Authors Dr Kneissel and Dr Kramer are employees of Novartis Pharma AG.

: Animal experiments were approved and performed under the Western Sydney LHD Animal Ethics Committee protocol 4174 and CMRI/CHW animal ethics protocol K338.